Clade Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Clade Therapeutics, Inc. - overview
Established
2020
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Founded in 2020 and based in Massachusetts, US, Clade Therapeutics, Inc. operates as a clinical drug development company that develops drugs for patients with cancer diseases. The company was founded by its CEO, Chad Cowan, CBO Jim Glasheen, Deepta Bhattacharya, and Gustavo Mostoslavsky. In April 2024, Century Therapeutics, Inc.
, a portfolio company of Avidity Partners, Venrock Healthcare Capital Partners, and DAFNA Capital Management, acquired Clade Therapeutics, Inc. from Bristol-Myers Squibb Company, Emerson Collective, LifeSci Partners, and Syncona Limited for USD 35 million. The company will receive an additional USD 10 million upon reaching certain milestones. Clade develops cell medicines, mainly iPSC-derived cells, to treat cancer and autoimmune diseases.
The company offers an αβ iT platform, which is an iPSC-derived cell therapy that provides iPSC-derived αβ T cells. The company uses induced pluripotent stem cells (iPSCs) to create adult human T cells, Treg cells, and B cells. These cells can be used to target and destroy cancer cells or suppress autoimmune responses. The firm’s pipeline program includes CAR-T (Chimeric Antigen Receptor T-cell) therapies for treating cancer, which have a combination of iPSC-derived CD8+ and CD4+ αβ CAR-T cells.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.cladetx.com
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.